Unternehmen Entasis Therapeutics Holdings Inc.
Aktien
A2N4R0
US2936141033
ETTX
Biotechnologie
Kurzporträt
Mitarbeiterzahl: 51
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Manoussos Perros
CEO | Chief Executive Officer | 56 | 01.05.15 |
Ruben Tommasi
CTO | Chief Tech/Sci/R&D Officer | 58 | 01.05.15 |
David Altarac
CTO | Chief Tech/Sci/R&D Officer | 63 | 04.11.19 |
Kyle Dow
IRC | Investor Relations Contact | - | - |
Matthew Ronsheim
PRN | Corporate Officer/Principal | 52 | 01.09.20 |
Anna Diaz Triola
PRN | Corporate Officer/Principal | - | 19.07.21 |
John Mueller
PRN | Corporate Officer/Principal | 64 | 01.05.15 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
David Hastings
BRD | Director/Board Member | 62 | 01.04.18 |
Director/Board Member | 58 | 01.08.17 | |
Heather Behanna
BRD | Director/Board Member | 49 | 01.08.17 |
David Meek
CHM | Chairman | 59 | 24.06.19 |
Marianne Zhen
BRD | Director/Board Member | 55 | 11.07.22 |
Manoussos Perros
CEO | Chief Executive Officer | 56 | 01.05.15 |
Pavel Raifeld
BRD | Director/Board Member | 40 | 11.07.22 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 47 851 779 | 44 441 302 ( 92,87 %) | 0 | 92,87 % |
Unternehmenskontakt
Sektor
% 1. Jan. | Kap. | |
---|---|---|
-0.49% | 103 Mrd. | |
+3.31% | 96.73 Mrd. | |
+1.66% | 21.31 Mrd. | |
-16.16% | 21.21 Mrd. | |
-6.82% | 18.79 Mrd. | |
-41.41% | 16.37 Mrd. | |
-22.87% | 13.68 Mrd. | |
+6.32% | 13.44 Mrd. | |
+21.46% | 10.98 Mrd. |